Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Autologous Muscle Derived Cells for injection into the external anal sphincter”In the company’s words, NCT04976153 on ClinicalTrials.gov
- Tested for
- Fecal Incontinence
- Main trialPhase 3
- “The objective of this study is the final assessment of clinical safety and efficacy of autologous autologous skeletal muscle derived cells for patients with urge fecal incontinence due to external anal sphincter dysfunction caused by its disruption and/or weakness.”In the company’s words, NCT04976153 on ClinicalTrials.gov
Other drugs for Fecal Incontinence
- IltamiocelCook MyoSite · Phase 3
- BioSphincterCellf Bio LLC · Phase 1
Coming up1
- 31 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2027 | Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026